Title |
Impact of mutational studies on the diagnosis and the outcome of high-risk myelodysplastic syndromes and secondary acute myeloid leukemia patients treated with 5-azacytidine
|
---|---|
Published in |
Oncotarget, April 2018
|
DOI | 10.18632/oncotarget.25046 |
Pubmed ID | |
Authors |
Marta Cabezón, Joan Bargay, Blanca Xicoy, Olga García, Josep Borrás, Mar Tormo, Sílvia Marcé, Carme Pedro, David Valcárcel, Maria-José Jiménez, Ramón Guàrdia, Laura Palomo, Salut Brunet, Ferran Vall-Llovera, Antoni Garcia, Evarist Feliu, Lurdes Zamora |
Abstract |
Myelodysplastic syndromes (MDS) are stem cell disorders caused by various gene abnormalities. We performed targeted deep sequencing in 39 patients with high-risk MDS and secondary acute myeloid leukemia (sAML) at diagnosis and follow-up (response and/or relapse), with the aim to define their mutational status, to establish if specific mutations are biomarkers of response to 5-azacytidine (AZA) and/or may have impact on survival. Overall, 95% of patients harbored at least one mutation. TP53, DNMT3A and SRSF2 were the most frequently altered genes. Mutations in TP53 correlated with higher risk features and shorter overall survival (OS) and progression free survival (PFS) in univariate analysis. Patients with SRSF2 mutations were associated with better OS and PFS. Response rate was 55%; but we could not correlate the presence of TET2 and TP53 mutations with AZA response. Patients with sAML presented more variations than patients with high-risk MDS, and usually at relapse the number of mutations increased, supporting the idea that in advanced stages of the disease there is a greater genomic complexity. These results confirm that mutation analysis can add prognostic value to high-risk MDS and sAML patients, not only at diagnosis but also at follow-up. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 2 | 50% |
Unknown | 2 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 75% |
Practitioners (doctors, other healthcare professionals) | 1 | 25% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 17 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 4 | 24% |
Student > Ph. D. Student | 2 | 12% |
Student > Postgraduate | 2 | 12% |
Student > Doctoral Student | 1 | 6% |
Student > Master | 1 | 6% |
Other | 3 | 18% |
Unknown | 4 | 24% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 5 | 29% |
Biochemistry, Genetics and Molecular Biology | 3 | 18% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 12% |
Immunology and Microbiology | 2 | 12% |
Nursing and Health Professions | 1 | 6% |
Other | 0 | 0% |
Unknown | 4 | 24% |